DANYELZA

This brand name is authorized in Israel, United States

Active ingredients

The drug DANYELZA contains one active pharmaceutical ingredient (API):

1 Naxitamab UNII 9K8GNJ2874 - NAXITAMAB

Naxitamab-gqgk binds to the glycolipid GD2. GD2 is a disialoganglioside that is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. In vitro, naxitamab-gqgk was able to bind to cell surface GD2 and induce complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC). Read about Naxitamab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
DANYELZA Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX21		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX21

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9010
Country: US	FDA, National Drug Code	Identifier(s): 73042-201